Aptevo Therapeutics Inc. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
Aptevo Therapeutics Inc. (APVO) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $4.07 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-05-10
- Aptevo Therapeutics Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $4.07M, a 92.57% increase year-over-year.
- Aptevo Therapeutics Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $2.82M, a 2.29% increase year-over-year.
- Aptevo Therapeutics Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $2.51M, a 11.01% decline year-over-year.
- Aptevo Therapeutics Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $10.75M, a 5.82% increase year-over-year.
- Aptevo Therapeutics Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $10.95M, a 11.67% increase from fiscal 2016.
- Aptevo Therapeutics Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $9.80M, a 64.92% decline from fiscal 2015.
- Aptevo Therapeutics Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $27.95M.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2018-03-31 | $4.07M 10-Q · filed 2018-05-10 | $6.89M derived: sum of 2 quarters · filed 2018-05-10 | $9.39M derived: sum of 3 quarters · filed 2018-05-10 | $20.14M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $5.32M derived: sum of 2 quarters · filed 2018-03-13 | $16.07M derived: sum of 3 quarters · filed 2018-03-13 | $10.95M 10-K · filed 2018-03-13 | |||
| 2017-09-30 | $2.51M 10-Q · filed 2017-11-13 | $13.26M derived: sum of 2 quarters · filed 2017-11-13 | $8.13M 10-Q · filed 2017-11-13 | $18.13M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-06-30 | $10.75M 10-Q · filed 2017-08-10 | $18.13M 10-Q · filed 2017-08-10 | $15.62M derived: sum of 3 quarters · filed 2018-05-10 | $18.43M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-03-31 | $2.11M 10-Q · filed 2018-05-10 | $7.38M 10-Q · filed 2017-05-12 | $4.87M derived: sum of 2 quarters · filed 2018-05-10 | $7.68M derived: sum of 3 quarters · filed 2018-05-10 | $17.84M derived: sum of 4 quarters · filed 2018-05-10 | ||
| 2016-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $5.57M derived: sum of 2 quarters · filed 2018-03-13 | $15.73M derived: sum of 3 quarters · filed 2018-03-13 | $9.80M 10-K · filed 2018-03-13 | $36.25M 10-K · filed 2017-03-31 | ||
| 2016-09-30 | $2.82M 10-Q · filed 2017-11-13 | $9.40M 10-Q · filed 2016-11-14 | $12.97M derived: sum of 2 quarters · filed 2017-11-13 | $7.05M 10-Q · filed 2017-11-13 | $27.51M 10-Q · filed 2016-11-14 | $29.17M derived: sum of 4 quarters · filed 2017-11-13 | |
| 2016-06-30 | $10.16M 10-Q · filed 2017-08-10 | $18.11M 10-Q · filed 2017-08-10 | $26.35M derived: sum of 3 quarters · filed 2017-08-10 | $32.79M derived: sum of 4 quarters · filed 2017-08-10 | |||
| 2016-03-31 | $7.95M 10-Q · filed 2017-05-12 | $16.19M derived: sum of 2 quarters · filed 2017-05-12 | $22.63M derived: sum of 3 quarters · filed 2017-05-12 | $29.57M derived: sum of 4 quarters · filed 2017-05-12 | |||
| 2015-12-31 | $8.24M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $14.68M derived: sum of 2 quarters · filed 2017-03-31 | $21.63M derived: sum of 3 quarters · filed 2017-03-31 | $27.95M 10-K · filed 2017-03-31 | |||
| 2015-09-30 | $6.44M 10-Q · filed 2016-11-14 | $13.38M derived: sum of 2 quarters · filed 2016-11-14 | $19.70M 10-Q · filed 2016-11-14 | ||||
| 2015-06-30 | $6.94M 10-Q/A · filed 2016-09-22 | $13.26M 10-Q/A · filed 2016-09-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |